Release - Exco InTouch Successfully Completes HIPAA Security Audit - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Release - Exco InTouch Successfully Completes HIPAA Security Audit

Source: Company News Release
Exco InTouch, the leading provider of patient engagement and data capture solutions for clinical research and healthcare providers, today announced that it has successfully undergone and completed an independent audit to assess compliance utilizing the National Institute of Standards and Technology (NIST) guidelines for Health Insurance Portability and Accountability Act (HIPAA) security.

HIPAA rules constitute a set of regulations from the US Department of Health & Human Services relating to any Protected Health Information (PHI) that identifies health or financial data of US citizens stored on computer systems. The Security Rule specifies a series of administrative, physical, and technical safeguards for covered entities and their business associates to use to assure the confidentiality, integrity, and availability of electronic PHI.

Dale Jessop, Chief Technology Officer at Exco InTouch commented “Security of data and the protection of personal information remain the highest priority for Exco InTouch. Whilst no formal certification for HIPAA exists, to be independently audited against NIST guidelines for HIPAA security provides further reassurance to our customers that Exco InTouch business operations are aligned to comply with HIPAA standards.”

Tim Davis, CEO and co-founder of Exco InTouch added “I am extremely proud of the team involved throughout the audit process, and also that of the 64 HIPAA citations we were audited on, no findings were reported". As a result of this audit, Exco InTouch customers (for whom the company provides mobile and digital patient engagement solutions), can continue to be assured that their programs comply with these stringent security safeguards.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here